PARP Inhibitor + Avastin Delays Cancer Progression When Used as Initial Treatment for Ovarian Cancer

(October 9, 2019)

Maintenance therapy with the PARP inhibitor Lynparza (olaparib) added to Avastin (bevacizumab) resulted in a significant and clinically meaningful delay in cancer progression in patients with advanced stage III-IV ovarian cancer  according to the... Continue Reading

Lynparza-Avastin Maintenance Delays Progression of Ovarian Cancer

(August 20, 2019)

Results from the phase III PAOLA-1 clinical trial in women with advanced ovarian cancer evaluating maintenance therapy with Lynparza (olaparib) plus Avastin (bevacizumab) compared to Avastin alone in women with or without BRCA gene mutations have been... Continue Reading

NCCN Updates Ovarian Cancer Guidelines

(March 26, 2019)

The NCCN has recently updated its ovarian cancer treatment guidelines and make the following significant changes. All patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer should have a genetic risk evaluation and BRCA1/2... Continue Reading

About The National Ovarian Cancer Coalition

(August 29, 2018)

Where do you go when you’re first delivered the news: “You have cancer”? For many women diagnosed with ovarian cancer, the answer is the National Ovarian Cancer Coalition (NOCC). With more than 80 chapters nationwide, a Web site ( Continue Reading

Newly Diagnosed with Ovarian Cancer? 10 Must Read Tips to be an Empowered Patient

(June 18, 2018)

For many years ovarian cancer has been referred to as “the silent killer” due to its vague, ignored, or misdiagnosed symp­toms. Because of this and the lack of ear­ly-detection tools, ovarian cancer often goes undiagnosed until it has reached the... Continue Reading

PARP – Checkpoint Inhibitor Combo Promising in Ovarian Cancer

(May 16, 2018)

CancerConnect News: The combination of a PARP inhibitor and a checkpoint inhibitor appears promising as treatment for patients with ovarian cancer, according to results of a clinical study reported at the 2018 Society for Gynecologic Oncology Annual... Continue Reading

Rubraca® Approved as Maintenance Treatment of Recurrent Ovarian Cancer

(April 9, 2018)

CancerConnect News: Rubraca® (rucaparib) has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.... Continue Reading

It’s in the Genes: Genetic Testing for Ovarian Cancer 

(March 15, 2018)

What your DNA reveals and why it’s worth knowing CancerConnect News: Ovarian cancer is often dubbed as the “silent killer” of women. The symptoms are vague—including bloating, fatigue, irregular bleeding, frequent urination, and back pain1 —making... Continue Reading

Chemo Bath Improves Ovarian Cancer Survival

(January 22, 2018)

CancerConnect News: A heated chemotherapy bath circulated throughout the abdomen after surgery can significantly prolong a woman’s survival with advanced ovarian cancer, according to the results of a study published in the prestigious New England Journal... Continue Reading

Rubraca Significantly Improves Survival Ovarian Cancer

(January 18, 2018)

CancerConnect News: According to the results of a recently published clinical trail the novel precision cancer medicine Rubraca® (rucaparib) improves the outcomes of individuals with advanced ovarian cancer. About Rubraca® Rubraca® is an oral taken... Continue Reading

Latest Ovarian Cancer News By Stage

Recurrent Ovarian Cancer

Sorry, there are no articles available for this cancer stage.

More Recurrent Ovarian Cancer

Screening/Prevention Ovarian Cancer

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Ovarian Cancer

Stage I Ovarian Cancer

Sorry, there are no articles available for this cancer stage.

More Stage I Ovarian Cancer

Stage II-IV Ovarian Cancer

Sorry, there are no articles available for this cancer stage.

More Stage II-IV Ovarian Cancer